Gregg Siegal new professor of Biophysical techniques for drug discovery at AIMMS

The Executive Board of the VU appoints Gregg Siegal as professor of the Biophysical techniques for drug discovery chair, starting 1 April 2018.

05/22/2018 | 2:18 PM

The chair focuses on the use of modern sensitive technologies to detect, characterize and solve 3 dimensional structures of organic molecules interacting with pharmaceutical targets. Part of the aim is to enhance the interaction between academic and industrial efforts to discover novel drugs to benefit unmet medical needs. In addition, the chair should complement the expertise in the O|2 Lab Building.

Novel Drug Discovery Technologies

Gregg Siegal is the co-founder and CEO of ZoBio, a Leiden, NL based company that develops and offers new solutions to small molecule drug discovery challenges. Beginning in his previous academic appointment, Siegal has developed NMR methods for screening collections of compounds for selective binding to a desired protein and determining the 3-dimensional structure of such complexes. More recently, ZoBio is pioneering high throughput protein engineering technologies. The goal of these efforts is to make the early stages of small molecule drug discovery faster and more successful.

The aim of the appointment - that has been made possible by the foundation “Professor Doctor W.Th.Nauta Fonds” - is to intensify the interaction between the research into drug discovery at the VU and industry. Professor Siegal already participates in the Marie Skłodowska-Curie Action Fragnet, coordinated by the AIMMS Division of Medicinal Chemistry. In addition, by providing strategic guidance to PhD students and collaborating on grant driven research projects, industry developed technology can move to academia and students will obtain a more complete education and be better equipped to contribute to developing new medications.

Gregg Siegal

Siegal received his PhD degree from the University of Rochester (NY, USA) in DNA replication studies. Subsequently he post-Doc’ed with Prof. Kurt Wüthrich at the ETH (Zürich, CH) and the Ludwig Institute for Cancer Research, where he began studies in biophysics based drug discovery. Siegal then moved to Leiden University where he received a fellowship from the Dutch Royal Scientific Society to build a research group. He was later appointed assistant professor in the Leiden Institute of Chemistry where his research group was active in developing new technologies and applying them to create new novel drugs. He subsequently left the LIC to focus on leading ZoBio.